Altos Labs acquires Dorian Therapeutics, a startup developing drugs that curb senescent cells

Altos Labs/Cellular rejuvenation programming

Altos Labs acquired Dorian Therapeutics, a Stanford spinout developing small-molecule senoblockers that target senescent cells—cells that stop dividing and accumulate in aging tissue. Dorian's technology modulates chromatin accessibility to reduce senescent cell burden and enhance stem cell function, with lead candidates showing promise in preclinical models of lung fibrosis and osteoarthritis.

• Dorian's senoblockers are small molecules targeting senescent cells; modulate chromatin accessibility to restore youthful gene expression.
• Preclinical efficacy demonstrated in lung fibrosis and osteoarthritis models by enhancing stem cell function.
• Terms undisclosed; acquisition strengthens Altos' cellular rejuvenation portfolio beyond epigenetic reprogramming alone.